The results of a six-month trial have shown that the schizophrenia treatment Invega causes significantly fewer metabolic effects compared to other treatments.

The study, which compared Invega and oral olanzapine showed a reduction in metabolic side effects, including changes in serum lipid levels and glucose levels, and weight side effects, which can increase the risk of long-term chronic health conditions such as diabetes and cardiovascular disease.

Flexivest Fourteen Research Centre, Cape Town, South Africa’s Dr DJH Niehaus said that metabolic changes as a result of antipsychotic treatment can impact on a patient’s self confidence and compliance with medication.

“Minimising treatment-related metabolic effects is an important clinical goal for the management of schizophrenia, and this study demonstrates that Invega can help meet this need,” Niehaus said.

The study also showed comparable efficacy between Invega and olanzapine in reducing the symptoms of schizophrenia, as assessed using the positive and negative syndrome scale and the clinical global impression scale.